Immix Biopharma, Inc.
IMMX· Nasdaq
Released Nov 7, 2025, after the close
10-Q filed Nov 7, 2025, 38 days after period end · 0001493152-25-021325
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | -$7.59M | -$7.15M | -$4.28M | -$1.54M |
| EPS Diluted | -$0.24 | -$0.24 | -$0.23 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immix Biopharma, Inc. · CIK 1873835 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Sep 30, 2025 · filed Nov 7, 2025 · 38 d after period end
+2.8% from the close of Nov 7, 2025 to the close of Nov 10, 2025, the first after the release.